HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.

Abstract
K2 and several similar purported "incense products" spiked with synthetic cannabinoids are abused as cannabis substitutes. We hypothesized that metabolism of JWH-073, a prevalent cannabinoid found in K2, contributes to toxicity associated with K2 use. Competition receptor binding studies and G-protein activation assays, both performed by employing mouse brain homogenates, were used to determine the affinity and intrinsic activity, respectively, of potential monohydroxylated (M1, M3-M5) and monocarboxylated (M6) metabolites at cannabinoid 1 receptors (CB1Rs). Surprisingly, M1, M4 and M5 retain nanomolar affinity for CB1Rs, while M3 displays micromolar affinity and M6 does not bind to CB1Rs. JWH-073 displays equivalent efficacy to that of the CB1R full agonist CP-55,940, while M1, M3, and M5 act as CB1R partial agonists, and M4 shows little or no intrinsic activity. Further in vitro investigation by Schild analysis revealed that M4 acts as a competitive neutral CB1R antagonist (K(b)∼40nM). In agreement with in vitro studies, M4 also demonstrates CB1R antagonism in vivo by blunting cannabinoid-induced hypothermia in mice. Interestingly, M4 does not block agonist-mediated responses of other measures in the cannabinoid tetrad (e.g., locomotor suppression, catalepsy or analgesia). Finally, also as predicted by in vitro results, M1 exhibits agonist activity in vivo by inducing significant hypothermia and suppression of locomotor activity in mice. In conclusion, the present study indicates that further work examining the physiological effects of synthetic cannabinoid metabolism is warranted. Such a complex mix of metabolically produced CB1R ligands may contribute to the adverse effect profile of JWH-073-containing products.
AuthorsLisa K Brents, Anna Gallus-Zawada, Anna Radominska-Pandya, Tamara Vasiljevik, Thomas E Prisinzano, William E Fantegrossi, Jeffery H Moran, Paul L Prather
JournalBiochemical pharmacology (Biochem Pharmacol) Vol. 83 Issue 7 Pg. 952-61 (Apr 01 2012) ISSN: 1873-2968 [Electronic] England
PMID22266354 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier Inc. All rights reserved.
Chemical References
  • Cannabinoids
  • Illicit Drugs
  • Indoles
  • Ligands
  • Naphthalenes
  • Receptor, Cannabinoid, CB1
  • JWH-073
  • GTP-Binding Proteins
Topics
  • Animals
  • Behavior, Animal (drug effects)
  • Binding, Competitive
  • Body Temperature (drug effects)
  • Brain (drug effects, metabolism)
  • Cannabinoids (chemistry, metabolism, pharmacology)
  • Cell Membrane (drug effects, metabolism)
  • Drug Antagonism
  • Drug Partial Agonism
  • GTP-Binding Proteins (metabolism)
  • Hydroxylation
  • Illicit Drugs (chemistry, metabolism, pharmacology)
  • Indoles (chemistry, metabolism, pharmacology)
  • Ligands
  • Male
  • Mice
  • Mice, Inbred Strains
  • Molecular Structure
  • Naphthalenes (chemistry, metabolism, pharmacology)
  • Protein Binding
  • Rats
  • Rats, Sprague-Dawley
  • Receptor, Cannabinoid, CB1 (agonists, antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: